Asset Details
Do you wish to reserve the book?
Tumor slice culture system to assess drug response of primary breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tumor slice culture system to assess drug response of primary breast cancer
Do you wish to request the book?
Tumor slice culture system to assess drug response of primary breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tumor slice culture system to assess drug response of primary breast cancer
2016
Overview
Background
The high incidence of breast cancer has sparked the development of novel targeted and personalized therapies. Personalization of cancer treatment requires reliable prediction of chemotherapy responses in individual patients. Effective selection can prevent unnecessary treatment that would mainly result in the unwanted side effects of the therapy. This selection can be facilitated by characterization of individual tumors using robust and specific functional assays, which requires development of powerful ex vivo culture systems and procedures to analyze the response to treatment.
Methods
We optimized culture methods for primary breast tumor samples that allowed propagation of tissue ex vivo. We combined several tissue culture strategies, including defined tissue slicing technology, growth medium optimization and use of a rotating platform to increase nutrient exchange.
Results
We could maintain tissue cultures for at least 7 days without losing tissue morphology, viability or cell proliferation. We also developed methods to determine the cytotoxic response of individual tumors to the chemotherapeutic treatment FAC (5-FU, Adriamycin [Doxorubicin] and Cyclophosphamide). Using this tool we designated tumors as sensitive or resistant and distinguished a clinically proven resistant tumor from other tumors.
Conclusion
This method defines conditions that allow ex vivo testing of individual tumor responses to anti-cancer drugs and therefore might improve personalization of breast cancer treatment.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V
Subject
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage
/ Biomedical and Life Sciences
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ Cancer
/ Complications and side effects
/ Cyclophosphamide - administration & dosage
/ Doxorubicin - administration & dosage
/ Drug Resistance, Neoplasm - genetics
/ Drug Screening Assays, Antitumor
/ Female
/ Fluorouracil - administration & dosage
/ Health Promotion and Disease Prevention
/ Humans
/ Oncology
